Abstract: Chitosan (CS) based materials in a form of composite with poly(lactic acid) (PLA) granules, films and freeze-dried scaffolds also with blend form with hydroxypropylocellulose (HPC), as well as dibutyrylchitin films were obtained. These structures are intended especially for controlled drug delivery systems, including transdermal and oral dosage forms. Excellent adhesion of biopolymer matrices to PLA microspheres or hydroxyapatite (HAp) particles was proven. The Iorder drug (ibuprofen (IBU)) release kinetics from obtained films is stated.
Introduction
Worldwide biopolymer market is continuously extending due to biotechnology and process engineering development, together with the increasing demand of environmental friendly material production [1] .
Novel biopolymeric materials find diverse applications in the medical and pharmaceutical sector [2, 3] . They are very useful especially in the fields of sustained drug release and tissue engineering.
Controlled drug release systems are composed of therapeutic substance enclosed in a degradable matrix, which, through slow hydrolysis in human body, release sufficient amounts of medicine in a prolonged time period. As bioerodible drug carriers, natural polymers, among others, chitosan, polylactide and dibutyrylchitin can be successfully applied. These materials can be effectively prepared in a form of nano-and microparticles [4] , beads [5] or films [6] . Mentioned biopolymers show full biocompatibility and also bioactivity [7] . Moreover, products of chitosan, dibutyrylchitin [8, 9, 10] and polylactide [11] biodegradation show no toxicity and can be easily metabolised within human body.
Development of implantation and bone tissue engineering leads nowadays to new biopolymer materials evaluation in term to replace former materials used for transplantation and tissue growing, like ceramic or metallic ones. Unique natural polymers, especially chitosan [12, 13, 14] , have great advantages in comparison to metal and ceramics, due to their bioactivity -ability to accelerate regeneration processes and also prevention from microbial infections at the cellular and tissue level. Moreover, biocompatible polymers do not cause immunological response. During tissue regeneration, such biopolymeric implants undergo biodegradation until their complete resorption.
Porous chitosan based scaffolds for bone tisue engineering applications can be prepared by range of methods e.g. electrospinning [15] , electrolysis [16] and freezedrying [17] . This paper presents a recent work on flat thin dibutyrylchitin drug carrier proposed as a transdermal dosage system. This device was made by polymer with model drug (ibuprofen) solution casting.
Other biopolymeric drug carriers proposed for oral administration are chitosan beads and films combined with polylactide microparticles encapsulating ibuprofen.
Finally, the preparation and comparison of some chitosan based scaffolds obtained by freeze-drying method will be presented.
Results and discussion

Morphology of obtained chitosan-based structures
Scanning electron microscopy and optical microscopy were used for biopolymer samples examination.
Microscopical investigations confirmed DBCH films, carrying IBU, transparency and homogenity. This means that model drug was dispersed within biopolymer matrix in a molecular form. In Figure 1 , SEM microphotographs of polylactide-chitosan acetate composite beads and films are shown. Emulsification with ethyl acetate evaporation process resulted in a wide range of polylactide microspheres diameters (1-20 mm), which show excellent adhesion to chitosan coating due to electrostatic interactions. Composite beads as well as films proved a very good mPLA's distribution within matrices and reduce water swelling ability (results not presented), which makes them more stable in the water environment than the pure chitosan acetate beads and films.
Lyophilized sponge-like biopolymer structures are presented in Figure 2 . Obtained scaffolds of good mechanical properties (not presented here) can be successfully used for the bone tissue growing. Significant morphology differences between CS acetate, HPC and their blend scaffolds are not distinct.
SEM analysis of chitosan acetate scaffolds containing HAp particles proved a good hydroxyapatite distribution within polymer matrix and its good adhesion to CS material ( Figure 3 ). 
Swelling kinetics and ibuprofen release studies from BDCH films
The process of water uptake by dibutyrylchitin films as well as the model drug release from them, were conducted in two water environments of pH=5.6 (skin acidity) and 7.2 (intestinal acidity).
The studies revealed the I-order kinetics of both analysed processes (Figure 4 ), according to equation 1.:
where:
y -analysed parameters under study: α -swelling degree [%] or f t -ratio of released drug [%]; A -constant equal to:
The process of DBCH film swelling leads to 16.5% -18% water uptake slightly rising with the pH increase. Maximum value of sample swelling degree is achieved after 25 hours for distilled water and about 60 h for phosphate buffer. Ibuprofen release process from DBCH flat matrix was conducted for more than 300 h. 62% of loaded ibuprofen was released to phosphate buffer within 250 h, whereas more rapid
release of ibuprofen was observed in case of distilled water. Moreover, only 32% of encapsulated drug was succesfully released to the medium of pH=5.6. 
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Ibuprofen release studies from mPLA-IBU/CS films
First results of IBU release kinetics from composite beads and films were presented in previous paper [18] . 
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The main disadvantage of obtained bi-polymer release systems was the occurrence of rapid drug release in the first phase of process (so called "burst effect"). To overcome this problem, it has been decided to cover the composite carriers with additional polylactide layers, through their spray coating with PLA solution in ethyl acetate. Here are present results of initial phase of IBU release from mPLA-IBU/CS films covered with PLA layers from both sides ( Figure 5 ). Although the drug amount released within 3 h from PLA covered sample slightly decreased in comparison to the drug ratio released from uncovered one, the significant reduction of the "burst effect" influence has been achieved.
Conclusions
Emulsification with ethyl acetate evaporation process resulted in polylactide microspheres encapsulating model drug, which were very well distributed within chitosan matrix. Both polymers shown excellent adhesion to each other due to their electrostatic interactions.
The amount of ibuprofen released within 3 h from a sample which was spray-coated with PLA layers slightly decreased in comparison to the drug ratio released from noncoated one, but the significant reduction of the "burst effect" influence has been achieved.
Scaffolds prepared from CS and HPC or their blends by freeze dried method are good material for application in tissue engineering due to the biodegradability and proper morphological structure. HAp introduced into polymeric structure accelerates natural process of osteogenesis. Application of ultrasounds allows for better dispersion of HAp in polymer matrix (without distinct degradation of polymer).
Kinetics of drug (IBU) release from thin films made from BDCH depends on media pH. The release is described by I -order equation and to pH =5.6 is much faster than to pH=7.2. Swelling of the films in the media is also fitted to I -order kinetics.
Experimental part
Chitosan (CS) powder of deacetylation degree 73.3% and viscosity 256 mPas was provided by Sea Fishery Institute in Gdynia, Poland. Chitosan was dissolved in 1% acetic acid and used in a form of solution after its purification by centrifugation (5400 rpm, 7 min). Polylactide (PLA) granulate was purchased from NatureWorks (USA). Ethyl acetate was used as a PLA solvent.
Ibuprofen (IBU) powder provided by Cardinal Pharma Trade, Lodz, Poland and hydroxyapatite (HAp) (Sigma Aldrich Laborchemikalien GmbH, Germany) were used as model active substances in the investigations of their comaptibility with biopolymer matrices and release studies. Other reagents were used in an analytical grade.
Preparation of dibutyrylchitin films containing model drug
Dibutyrylchitin is a non water soluble chitin derivative which dissolves easily in ethanol. Obtained DBCH 1% solution in 96% ethanol with an ibuprofen amount equal to 20 weight % of the polymer. Known volumes of described solution were poured at glass plates and the solvent evaporated at ambient temperature, which resulted in transparent DBCH films formation (80 μm thick) containing the model drug distributed in a molecular form.
Morphology of DBCH-IBU samples was studied as well as its swelling kinetics and the drug release kinetics in distilled water (pH=5.6) and phosphate buffer (pH=7.2).
Preparation of composite mPLA and CS beads and films containing model drug
Emulsification with solvent evaporation method [19] was applied to prepare polylactide microspheres in chitosan solution suspension (Figure 6 ).
Firstly, two (hydrophobic and hydrophilic) biopolymer solutions were obtained. The inner phase of emulsion was composed of 2.5% w/v hydrophobic PLA solution in ethyl acetate with addition of model drug (PLA to IBU weight ratio was 5:1). The outer water phase (1% acetic acid) contained 1% of chitosan together with an amount of poly(vinyl alcohol) used as an emulsion stabilizer. In the second step two biopolymer solutions were mixed together and emulsification occurred during biphasic liquid sonication (21.5 kHz). After obtaining stable O/W emulsion, the whole system underwent gentle mixing (200 rpm, magnetic stirrer) and ethyl acetate evaporation from the inner phase droplets at 50 o C. This process resulted in polylactide microparticles with encapsulated ibuprofen precipitation (diameters ranged from 1 up to 50 microns). At last, from the suspension of PLA microparticles with the molecularly dispersed model drug (mPLA-IBU) in chitosan solution, composite beads (avg. diameter of 1.5 cm) and films (70 μm thick) were formed as a novel bi-polymer prolonged release oral dosage forms. Films were obtained by the suspension casting and solvent evaporation whereas composite beads were formed by the chitosan droplets coacervation in the basic environment (1% tripolyphosphate in water solution, pH=9.5). In the end, mPLA-IBU/CS beads were collected on sieve and freeze-dried for further analysis. The scanning electron microscopy (SEM) morphology analysis of prepared composite films and beads was conducted. Initial results of drug release kinetics from mPLA-IBU/CS matrices were presented elsewhere.
Preparation of chitosan based freeze-dried scaffolds
Porous structures based on two biopolymers: chitosan (CS) and hydroxypropylocellulose were obtained through the pre-freezed polymer solutions lyophilization. Initially CS was dissolved in 1% acetic acid and HPC in distilled water. The blend solution of mentioned polymers (CS to HPC weight ratio was 1:1) were also prepared. Moreover, known amount of hydroxyapatite (HAp) was dispersed in CS solution by an ultrasounds treatment due to better dispersion of HAp particles (5min, f=100Hz in 80W power generator). Ultrasounds of low power and short time of acting do effect distinct degradation of chitozan [20, 21] . Later the solution were mixed using magnetic stirrer for 5 minutes. Weight fraction of HAp in the composite was equal to 10%. Human bones contain about 60% of HAp [22] . Implant systems containing biodegradable polymers may have much lower amount of HAp needed only for starting a regeneration process of own bones. Polymer undergoes whole absorption by organism. Polymers composites with higher than 20% by weight of HAp are characterized by bad mechanical properties, they are crisp.
Then, mentioned solutions were cast onto Petri dishes and put in a freezer (minus 27 o C) for 24 h. Finally, frozen biopolymeric solutions were dried through solvents sublimation in deep vacuum conditions. This resulted in highly porous scaffolds, whose morphology through microscopy (optical and SEM) was examined.
